GB262 is a novel PD-L1/CD55 bispecific antibody that has been shown to suppress PANC-1 tumor growth in mice by increasing T cell activation, as well as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) [175]. Here, CD55 is linked to neoplasm.